Table 1 Descriptive statistics of the analyses sample from the Luxembourg Parkinson’s Disease Study
Variable | PD | Control | Missing values | |
|---|---|---|---|---|
PD (%) | Control (%) | |||
Cases vs. controls | 147 | 162 | 0 | 0 |
Female subjects | 31.5% | 35.8% | 0 | 0 |
Age at basic assessment (mean ± SD) | 69.3 ± 8.6 | 63.3 ± 8.3 | 0 | 0 |
Body mass index (mean ± SD) | 27.3 ± 4.5 | 27.9 ± 4.8 | 0.7 | 0 |
Sniff score (mean ± SD) | 7.1 ± 3.4 | 12.7 ± 2.1 | 0 | 0 |
Diabetes | 4.1% | 3.1% | 0 | 0 |
Non-motor symptoms questionnaire score (NMS-PD) (mean ± SD) | 9.3 ± 5.1 | 3.9 ± 3.9 | 9.5 | 3.7 |
Constipation | 36.7% | 6.2% | 0 | 0 |
PD disease duration since diagnosis | 5.9 ± 5.7 | – | 6.1 | – |
UPDRS-part I (mean ± SD) | 10.0 ± 5.9 | 4.5 ± 4.4 | 3.4 | 3.1 |
UPDRS-part II (mean ± SD) | 11.8 ± 8.1 | 1.3 ± 2.8 | 1.4 | 2.4 |
UPDRS-part III (mean ± SD) | 34.6 ± 16.1 | 2.3 ± 2.9 | 1.4 | 0 |
UPDRS-part IV (mean ± SD) | 1.7 ± 3.2 | – | 1.4 | – |
Hoehn and Yahr (mean ± SD) | 2.2 ± 0.6 | – | 0 | – |
L-DOPA intake | 66.7% | 0% | 0 | 0 |
Dopamine agonist intake | 56.5% | 0% | 0 | 0 |
MAO-B inhibitor intake | 41.5% | 0% | 0 | 0 |
COMT inhibitor intake | 4.1% | 0% | 0 | 0 |